Does Collegium Pharmaceutical (COLL) Pay a Dividend? (2026)

Last updated November 2026

Short answer

No. Collegium Pharmaceutical (COLL) pays no dividend, so the yield is 0% and the position generates no income while you hold it. Its earnings position, ~$38 million / ~23x, is the reason that matters most: companies typically start paying only once earnings and free cash flow are durable enough to support a standing commitment. All of COLL's return has to come from the share price. Verify the current policy on COLL's investor relations page.

Does Collegium Pharmaceutical (COLL) pay a dividend?

No. There is no dividend on COLL in our data and the yield is 0%. Figures combine the fourth quarter of 2025 with the first nine months of 2026, at a share price of about $25.03 on November 20, 2026 and about 31.1 million shares outstanding. Adjusted figures exclude large non-cash items, mainly about $55 million a quarter of amortization on acquired drug rights, which is why GAAP diluted EPS for the first nine months of 2026 was only about $0.64 and the trailing GAAP P/E is near 23. A multiple near 3 times adjusted earnings is low for a profitable drug company and shows how much the market discounts the pain brands. The $239 million of convertible notes convert at about $36.56 a share, well above the current price.

Plainly: if you are holding COLL for income, it does not provide any. The only way a position in it puts cash in your pocket is if you sell shares.

Why COLL pays no dividend

Collegium Pharmaceutical's earnings position (~$38 million / ~23x) is the constraint. A dividend is a standing commitment that a board is very reluctant to cut once started, because a cut is read as a signal about the business. Companies therefore wait until profits and free cash flow are durable before starting one, and many never do, preferring buybacks, which can be paused without the same signalling cost.

Retaining cash is not a weakness in itself. A company that can reinvest a dollar at a high return creates more value by keeping it than by paying it out. The question is whether Collegium Pharmaceutical is actually earning that return on what it reinvests, which is a business question, not a dividend question.

What would have to change for COLL to start paying

Consistent profitability first, then free cash flow that comfortably exceeds what the business needs to keep growing, and then a management view that it has run out of better uses for the money. Those show up in the quarterly numbers well before any announcement, so the results are the place to watch. The press releases come later. We are not predicting whether or when that happens.

Where investors get income instead

The common approach is to hold COLL for the growth exposure and get income from somewhere else in the portfolio, so each position does one job. The income side means dividend-paying stocks, dividend ETFs, or short-term bond and Treasury funds, sized so the income side covers what you need.

Walnut is informational and is not an investment adviser. None of these are recommendations.

Tax: what a zero-dividend stock changes

With no dividend there is no income to report while you hold COLL, so nothing is taxable until you sell. At sale you owe capital-gains tax on the gain, at long-term rates if you held for more than a year. Compared with a dividend payer in a taxable account, which generates a tax bill every year whether you spend the cash or reinvest it, that deferral is a small structural advantage. See how stocks are taxed. This is not tax advice.

The bottom line on the COLL dividend

There is not one. Collegium Pharmaceutical (COLL) is a total-return holding: it either works through the share price or it does not work. If you own it, own it for that reason, and build the income part of your portfolio elsewhere. For the full picture see the COLL guide. Walnut can show how COLL fits your real portfolio. It is not an investment adviser.

Your questions about Collegium Pharmaceutical

Ask Walnut's AI anything about COLL and see how it fits what you own.

FAQ

Does Collegium Pharmaceutical (COLL) pay a dividend?

+

No. Collegium Pharmaceutical has no dividend on record, so the yield is 0% and holding COLL produces no income. Collegium Pharmaceutical directs its cash back into the business, through research, capacity, acquisitions, or buybacks. Every dollar of return from COLL has to come from the share price. Verify the current policy on COLL's investor relations page, since a board can start a dividend at any time.

Why doesn't COLL pay a dividend?

+

Collegium Pharmaceutical directs its cash back into the business, through research, capacity, acquisitions, or buybacks. Paying nothing is a deliberate choice, not a failure. A growth company that can reinvest at high returns creates more value per dollar retained than it would by handing that dollar to shareholders.

Will COLL ever pay a dividend?

+

Nobody can say, and we will not guess. What usually has to happen first is a stretch of durable profitability and positive free cash flow, with enough left over after reinvestment that the company runs out of better uses for the money. Those show up in the quarterly results well before any announcement. Companies also often start with buybacks before a dividend, because a buyback carries no ongoing commitment.

What is COLL's dividend yield?

+

0%. There is no dividend, so there is no yield. This matters for planning: if you are building an income portfolio, COLL contributes nothing to the income side and its entire contribution is price return. It also means the position generates no taxable income while you hold it.

How do I get income if I own COLL?

+

The usual approach is to pair a non-payer like COLL with holdings that do pay: dividend stocks, dividend ETFs, or bond funds, sized so the income side of the portfolio meets your needs while the growth side stays intact. Some investors sell covered calls on positions they hold, though that caps the upside that is the whole reason to own a growth name. See our guides to the best dividend stocks and best dividend ETFs. Walnut is not an investment adviser.

Do I owe tax on COLL if it pays no dividend?

+

Not while you hold it. With no dividend there is no income to report, so nothing is taxable until you sell. At that point you owe capital-gains tax on the gain, at long-term rates if you held for more than a year and at ordinary-income rates if you did not. That deferral is a genuine, if minor, advantage of non-payers in a taxable account. This is not tax advice.

Is COLL a bad stock for income investors?

+

It is the wrong tool for that job, which is not the same as a bad company. If you need cash from your portfolio, a stock paying nothing forces you to sell shares to generate it, which means selling into whatever price the market happens to offer. Investors who want COLL's growth exposure and also want income typically hold both kinds of position and give each one job.

Walnut is informational, not investment advice. Dividend figures on this page come from a November 2026 data pull and are approximate; verify the current yield, amount, schedule, and policy with COLL's investor relations page or your broker before acting on them.

Dividends on similar stocks